Patent Portfolio

Updated: August 12, 2007

Lpath has achieved a broad and deep intellectual-property position in the bioactive lipid area. The Company's patent portfolio is comprehensive with over 26 issued or pending patents in the U.S. alone, with corresponding international filings. A number of our issued patents and pending patent applications concern the use of reagents and methods designed to interfere with the actions of bioactive lipids involved in human disease. Our intellectual-property portfolio includes compositions of matter that specifically bind to sphingolipids and sphingolipid metabolites. These reagents, including antibodies, have already found, or might find in the future, use in the diagnosis and treatment of various diseases and disorders, including cardiovascular/cerebrovascular disease, cancer, inflammation, autoimmune disorders, ocular disease and angiogenesis. The Company has also obtained issued claims on sphingolipid targets (e.g., receptors, signaling sphingolipids) and methods for using such targets in drug discovery screening efforts. In short, the Company believes that its patent estate will provide broad, commercially significant coverage of antibodies, receptors, enzymes, or other moieties that bind to a lysolipid (or a sphingolipid metabolite), for diagnostic, therapeutic, or screening purposes.

Note that many of the Company's patents and patent applications were filed before October 2004, when Medlyte, Inc. changed its name to Lpath Therapeutics, Inc. (which then became Lpath, Inc. in 2005).

In 2005, Lpath purchased eight issued patents formerly assigned to Atairgin Technologies, Inc. and LPL Technologies, Inc. These patents cover compositions of matter and methods in the cancer diagnostics and therapeutics arenas relating to lipid-signaling pathways.

The following is a partial list of U.S. patents and published U.S. patent applications owned by the Company.

U.S. Issued Patents (partial list)

  1. 7,169,390 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
  2. 6,534,323 Compositions and methods for early detection of heart disease
  3. 6,881,546 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
  4. 6,210,976 Methods for early detection of heart disease
  5. 6,534,322 Kits for early detection of heart disease
  6. 6,858,383 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
  7. 6,500,633 Method of detecting carcinomas
  8. 6,485,922 Methods for detecting compounds which modulate the activity of an LPA receptor
  9. 6,461,830 Determining existence of preeclampsia in pregnancies by measuring levels of glycerophosphatidyl compounds, glycerophosphatidycholine, lysophospholipids and lysophosphatidylcholine
  10. 6,448,023 Enzyme method for detecting sphingosine-1-phosphate (S1P)
  11. 6,380,177 LPA analogs as agonists of the Edg2 LPA receptor
  12. 6,255,063 Disease conditions by measuring lysophosphatidic acid
  13. 6,248,553 Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
  14. 6,716,595 Method for detecting sphingosine-1-phosphate (S1P) for cancer detection

U.S. Patents pending (partial list)

  1. Pending Methods for decreasing immune response and treating immune conditions
  2. Pending Compositions & methods for the treatment and prevention of cancer, angiogenesis, and inflammation
  3. Pending Compositions, methods and medical devices for the treatment and prevention of myocardial ischemia and acute coronary syndrome
  4. Pending Compositions and methods for binding sphingosine-1-phosphate
  5. Pending Compositions and methods for the treatment and prevention of ocular conditions
  6. Pending Novel bioactive lipid derivatives, and methods of making and using same
  7. Pending Immune-derived moieties reactive against bioactive lipids, and methods of making and using same
  8. Pending Methods and reagents for detecting bioactive lipids
  9. Pending Immune-derived moieties reactive against lysophosphatidic acid
  10. Pending Compositions and methods for binding lysophosphatidic acid

It is important to note that Lpath has corresponding international filings (most typically in Europe, Japan, Canada, and Australia).